Cytocom is a biopharmaceutical company. Co.'s product candidate, Entolimod is a Toll-like receptor 5 (TLR5) agonist, which Co. is developing as a medical radiation countermeasure for reducing the risk of death following exposure to potentially lethal irradiation Acute Radiation Syndrome. Co.'s other product candidate, Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, a secretory non-glycosylated version of entolimod Co. is also developing through its subsidiary, Panacela Labs, Inc. Two randomized, placebo-controlled, dose-ranging studies of Mobilan in men with prostate cancer are ongoing in the Russian Federation. The CBLI average annual return 10 years is shown above.
The Average Annual Return on the CBLI average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CBLI average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CBLI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|